Clinical trials
ANCA Associated Systemic Vasculitis clinical trials
Below are recruiting anca associated systemic vasculitis clinical trials, each written for real people, not researchers. We’re tracking 50 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06277427Recruiting
CAR-T cell therapy for refractory vasculitis and lupus nephritis
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
Wuhan, HubeiAges 18–70 - NCT06462768Recruiting
Study of immune cell activity in systemic sclerosis
This study looks at a specific type of immune cell activity (called neutrophil extracellular traps) in the blood of people with systemic sclerosis, other connective tissue diseases, and healthy volunteers. It aims to understand how these cells may be involved in the disease and could lead to better treatments.
ReimsAges 18 years+ - NCT07746180RecruitingPhase 2
Obinutuzumab and low-dose steroids for new kidney disease
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
BeijingAges 18 years+ - NCT06642870Recruiting
Self-management programme for rare rheumatic conditions
This trial is developing a self-management programme for people with rare rheumatic conditions like lupus, vasculitis, myositis, or Sjogren syndrome. It aims to help participants better manage their condition and improve their quality of life.
BristolAges 18 years+ - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+ - NCT07526350RecruitingEarly Phase 1
MTS109 for Hard-to-Treat Autoimmune Diseases
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07413341RecruitingPhase 1
Study of new drug TI-0032-III for hard-to-treat autoimmune diseases
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07305116RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT07301164RecruitingEarly Phase 1
BCT301 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell treatment called BCT301 for people with certain autoimmune diseases like lupus or scleroderma that haven't gotten better with standard medicines. It aims to see if this treatment can help control the disease.
BeijingAges 18–80 - NCT07251179Recruiting
Understanding immune cells in autoimmune diseases and immune deficiencies
This study looks at immune cells in people with certain autoimmune diseases or immune deficiencies. The goal is to understand how these cells work, which may help improve future treatments.
StrasbourgAges 18–70 - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT06685042RecruitingPhase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
Rome, LazioAges 18–65 - NCT07203404RecruitingEarly Phase 1
A study of a universal CAR-T cell therapy for autoimmune diseases
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07168161RecruitingPhase 3
BDB-001 for ANCA vasculitis (GPA/MPA) trial
This trial tests a new drug called BDB-001 for people with a type of blood vessel inflammation (ANCA vasculitis, specifically GPA or MPA). It aims to see if adding BDB-001 to standard treatment can help control the disease better.
Beijing, Beijing MunicipalityAges 18–75 - NCT07160608RecruitingPhase 2
Study of Tarperprumig for ANCA-associated vasculitis
This trial tests a new drug (tarperprumig) for people with active ANCA-associated vasculitis (GPA or MPA). The goal is to see if it is safe and effective for treating the disease, especially when standard treatments like rituximab or cyclophosphamide are being considered.
Ciudad de Buenos AiresAges 18–80 - NCT06611696RecruitingPhase 4
Avacopan vs lower-dose steroids for new vasculitis
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
Toyoake, Aichi-kenAges 18 years+ - NCT07150000Recruiting
Rheumatic disease research study for patients and healthy volunteers
This study is for people with certain rheumatic conditions (like arthritis, lupus, or vasculitis) and for healthy volunteers. It aims to learn more about these diseases and improve how they are treated.
Bonn, North Rhine-WestphaliaAges 18 years+ - NCT07151521Recruiting
FAPI PET/CT in ANCA vasculitis with lung disease
This study uses a special PET/CT scan (called FAPI) to look at inflammation in people with ANCA-associated vasculitis and interstitial lung disease. It may help doctors see how active the disease is and guide treatment.
ShanghaiAges 18 years+ - NCT07089121RecruitingPhase 1/Phase 2
Descartes-08 for young people with autoimmune diseases
This trial tests a new therapy called Descartes-08 for children, teens, and young adults with autoimmune conditions like lupus, myasthenia gravis, or dermatomyositis. It aims to see if it can help control moderate disease that hasn't responded well enough to other treatments.
Washington D.C., District of ColumbiaAges 12 years+ - NCT07077304Recruiting
Cardiac imaging study for inflammatory heart diseases
This study uses heart scans (MRI or nuclear imaging) to better understand inflammatory heart conditions. If you have a suspected inflammatory heart disease and are already scheduled for one of these scans, you may be able to join.
ParisAges 18 years+ - NCT06980597RecruitingPhase 1
Testing OL-108 for active autoimmune diseases
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
BeijingAges 18–65 - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+
Hear when a new ANCA Associated Systemic Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for anca associated systemic vasculitis?
- Yes. Clin2 currently lists 50 recruiting anca associated systemic vasculitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a anca associated systemic vasculitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a anca associated systemic vasculitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.